Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
This study is being carried out to see if adding ZD1839 to other standard supportive care is
more effective than standard supportive care alone for the treatment of patients with NSCLC
whose disease has recurred after previous chemotherapy treatment.